We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HilleVax, Inc (HLVX), Lexicon Pharmaceuticals (LXRX) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...
Oppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Biomea Fusion (BMEA – Research Report), with a price ...
pharmaphorum3d
Novartis adds clinical-stage protein degrader from Arvinas
Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in a deal worth over $1 ...
pharmaphorum3d
Pfizer puts up $1bn to buy into Arvinas breast cancer programme
Arvinas reported phase 1 results with ARV-471 last December which backed the drug's mechanism of action and provided encouraging early results on safety and efficacy, including a reduction in ...
Yahoo Finance4d
ARVN Interactive Stock Chart | Arvinas, Inc. Stock - Yahoo Finance
At close: March 31 at 4:00:02 PM EDT ...
First Capital (NASDAQ:FCAP) Shares Pass Above Two Hundred Day Moving Average – What’s Next?
First Capital, Inc. (NASDAQ:FCAP – Get Free Report)’s share price passed above its 200-day moving average during trading on ...
Technology Networks2d
Unlocking the Potential of PROTACs in Drug Discovery
To explore how PROTACs are transforming drug discovery, we spoke with Robyn Stoller, business development manager at Cytiva.